nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferoxamine—chronic kidney failure—Calcitriol—psoriasis	0.458	0.54	CpDpCtD
Deferoxamine—chronic kidney failure—Cholecalciferol—psoriasis	0.39	0.46	CpDpCtD
Deferoxamine—Angioedema—Hydrocortisone—psoriasis	0.000105	0.000694	CcSEcCtD
Deferoxamine—Infection—Cyclosporine—psoriasis	0.000105	0.000693	CcSEcCtD
Deferoxamine—Nervous system disorder—Cyclosporine—psoriasis	0.000104	0.000684	CcSEcCtD
Deferoxamine—Thrombocytopenia—Cyclosporine—psoriasis	0.000104	0.000683	CcSEcCtD
Deferoxamine—Abdominal pain—Mycophenolic acid—psoriasis	0.000103	0.000682	CcSEcCtD
Deferoxamine—Body temperature increased—Mycophenolic acid—psoriasis	0.000103	0.000682	CcSEcCtD
Deferoxamine—Dizziness—Hydroxyurea—psoriasis	0.000103	0.000681	CcSEcCtD
Deferoxamine—Anaphylactic shock—Mycophenolate mofetil—psoriasis	0.000103	0.000681	CcSEcCtD
Deferoxamine—Oedema—Mycophenolate mofetil—psoriasis	0.000103	0.000681	CcSEcCtD
Deferoxamine—Asthma—Methotrexate—psoriasis	0.000103	0.000678	CcSEcCtD
Deferoxamine—Skin disorder—Cyclosporine—psoriasis	0.000103	0.000678	CcSEcCtD
Deferoxamine—Angiopathy—Dexamethasone—psoriasis	0.000103	0.000676	CcSEcCtD
Deferoxamine—Angiopathy—Betamethasone—psoriasis	0.000103	0.000676	CcSEcCtD
Deferoxamine—Infection—Mycophenolate mofetil—psoriasis	0.000103	0.000676	CcSEcCtD
Deferoxamine—Convulsion—Prednisolone—psoriasis	0.000102	0.000674	CcSEcCtD
Deferoxamine—Eosinophilia—Methotrexate—psoriasis	0.000102	0.000671	CcSEcCtD
Deferoxamine—Shock—Mycophenolate mofetil—psoriasis	0.000102	0.00067	CcSEcCtD
Deferoxamine—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000101	0.000667	CcSEcCtD
Deferoxamine—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.000101	0.000666	CcSEcCtD
Deferoxamine—Arrhythmia—Betamethasone—psoriasis	0.000101	0.000666	CcSEcCtD
Deferoxamine—Arrhythmia—Dexamethasone—psoriasis	0.000101	0.000666	CcSEcCtD
Deferoxamine—Tachycardia—Mycophenolate mofetil—psoriasis	0.000101	0.000664	CcSEcCtD
Deferoxamine—Skin disorder—Mycophenolate mofetil—psoriasis	0.0001	0.000661	CcSEcCtD
Deferoxamine—Bradycardia—Prednisone—psoriasis	0.0001	0.000661	CcSEcCtD
Deferoxamine—Convulsion—Hydrocortisone—psoriasis	9.99e-05	0.000658	CcSEcCtD
Deferoxamine—Vomiting—Hydroxyurea—psoriasis	9.94e-05	0.000655	CcSEcCtD
Deferoxamine—Angioedema—Triamcinolone—psoriasis	9.92e-05	0.000654	CcSEcCtD
Deferoxamine—Abdominal discomfort—Methotrexate—psoriasis	9.87e-05	0.00065	CcSEcCtD
Deferoxamine—Erythema—Dexamethasone—psoriasis	9.85e-05	0.000649	CcSEcCtD
Deferoxamine—Erythema—Betamethasone—psoriasis	9.85e-05	0.000649	CcSEcCtD
Deferoxamine—Myalgia—Hydrocortisone—psoriasis	9.82e-05	0.000647	CcSEcCtD
Deferoxamine—Hallucination—Prednisone—psoriasis	9.81e-05	0.000646	CcSEcCtD
Deferoxamine—Headache—Hydroxyurea—psoriasis	9.79e-05	0.000645	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	9.75e-05	0.000642	CcSEcCtD
Deferoxamine—Connective tissue disorder—Prednisone—psoriasis	9.69e-05	0.000638	CcSEcCtD
Deferoxamine—Hypotension—Mycophenolate mofetil—psoriasis	9.65e-05	0.000636	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Cyclosporine—psoriasis	9.65e-05	0.000636	CcSEcCtD
Deferoxamine—Anaphylactic shock—Prednisolone—psoriasis	9.64e-05	0.000635	CcSEcCtD
Deferoxamine—Oedema—Prednisolone—psoriasis	9.64e-05	0.000635	CcSEcCtD
Deferoxamine—Dysuria—Methotrexate—psoriasis	9.62e-05	0.000634	CcSEcCtD
Deferoxamine—Paraesthesia—Cyclosporine—psoriasis	9.51e-05	0.000626	CcSEcCtD
Deferoxamine—Shock—Prednisolone—psoriasis	9.48e-05	0.000625	CcSEcCtD
Deferoxamine—Dyspnoea—Cyclosporine—psoriasis	9.44e-05	0.000622	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	9.41e-05	0.00062	CcSEcCtD
Deferoxamine—Anaphylactic shock—Hydrocortisone—psoriasis	9.41e-05	0.00062	CcSEcCtD
Deferoxamine—Oedema—Hydrocortisone—psoriasis	9.41e-05	0.00062	CcSEcCtD
Deferoxamine—Convulsion—Triamcinolone—psoriasis	9.41e-05	0.00062	CcSEcCtD
Deferoxamine—Tachycardia—Prednisolone—psoriasis	9.4e-05	0.00062	CcSEcCtD
Deferoxamine—Infection—Hydrocortisone—psoriasis	9.35e-05	0.000616	CcSEcCtD
Deferoxamine—Nausea—Hydroxyurea—psoriasis	9.28e-05	0.000612	CcSEcCtD
Deferoxamine—Paraesthesia—Mycophenolate mofetil—psoriasis	9.28e-05	0.000611	CcSEcCtD
Deferoxamine—Pruritus—Mycophenolic acid—psoriasis	9.26e-05	0.00061	CcSEcCtD
Deferoxamine—Shock—Hydrocortisone—psoriasis	9.26e-05	0.00061	CcSEcCtD
Deferoxamine—Myalgia—Triamcinolone—psoriasis	9.24e-05	0.000609	CcSEcCtD
Deferoxamine—Nervous system disorder—Hydrocortisone—psoriasis	9.23e-05	0.000608	CcSEcCtD
Deferoxamine—Eye disorder—Prednisone—psoriasis	9.21e-05	0.000607	CcSEcCtD
Deferoxamine—Dyspnoea—Mycophenolate mofetil—psoriasis	9.21e-05	0.000607	CcSEcCtD
Deferoxamine—Tachycardia—Hydrocortisone—psoriasis	9.19e-05	0.000605	CcSEcCtD
Deferoxamine—Infestation—Methotrexate—psoriasis	9.18e-05	0.000604	CcSEcCtD
Deferoxamine—Infestation NOS—Methotrexate—psoriasis	9.18e-05	0.000604	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Cyclosporine—psoriasis	9.14e-05	0.000602	CcSEcCtD
Deferoxamine—Skin disorder—Hydrocortisone—psoriasis	9.14e-05	0.000602	CcSEcCtD
Deferoxamine—Pain—Cyclosporine—psoriasis	9.06e-05	0.000597	CcSEcCtD
Deferoxamine—Renal failure—Methotrexate—psoriasis	9.02e-05	0.000594	CcSEcCtD
Deferoxamine—Angioedema—Betamethasone—psoriasis	9e-05	0.000593	CcSEcCtD
Deferoxamine—Angioedema—Dexamethasone—psoriasis	9e-05	0.000593	CcSEcCtD
Deferoxamine—Diarrhoea—Mycophenolic acid—psoriasis	8.96e-05	0.00059	CcSEcCtD
Deferoxamine—Angiopathy—Prednisone—psoriasis	8.94e-05	0.000589	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	8.92e-05	0.000588	CcSEcCtD
Deferoxamine—Immune system disorder—Prednisone—psoriasis	8.9e-05	0.000586	CcSEcCtD
Deferoxamine—Anaphylactic shock—Triamcinolone—psoriasis	8.86e-05	0.000584	CcSEcCtD
Deferoxamine—Oedema—Triamcinolone—psoriasis	8.86e-05	0.000584	CcSEcCtD
Deferoxamine—Pain—Mycophenolate mofetil—psoriasis	8.83e-05	0.000582	CcSEcCtD
Deferoxamine—Arrhythmia—Prednisone—psoriasis	8.8e-05	0.00058	CcSEcCtD
Deferoxamine—Infection—Triamcinolone—psoriasis	8.8e-05	0.00058	CcSEcCtD
Deferoxamine—Hypotension—Hydrocortisone—psoriasis	8.79e-05	0.000579	CcSEcCtD
Deferoxamine—Shock—Triamcinolone—psoriasis	8.72e-05	0.000574	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Cyclosporine—psoriasis	8.66e-05	0.00057	CcSEcCtD
Deferoxamine—Dizziness—Mycophenolic acid—psoriasis	8.66e-05	0.00057	CcSEcCtD
Deferoxamine—Paraesthesia—Prednisolone—psoriasis	8.65e-05	0.00057	CcSEcCtD
Deferoxamine—Tachycardia—Triamcinolone—psoriasis	8.65e-05	0.00057	CcSEcCtD
Deferoxamine—Erythema—Prednisone—psoriasis	8.58e-05	0.000565	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Hydrocortisone—psoriasis	8.57e-05	0.000565	CcSEcCtD
Deferoxamine—Convulsion—Dexamethasone—psoriasis	8.54e-05	0.000562	CcSEcCtD
Deferoxamine—Convulsion—Betamethasone—psoriasis	8.54e-05	0.000562	CcSEcCtD
Deferoxamine—Paraesthesia—Hydrocortisone—psoriasis	8.45e-05	0.000557	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	8.45e-05	0.000556	CcSEcCtD
Deferoxamine—Urticaria—Cyclosporine—psoriasis	8.41e-05	0.000554	CcSEcCtD
Deferoxamine—Myalgia—Dexamethasone—psoriasis	8.39e-05	0.000553	CcSEcCtD
Deferoxamine—Myalgia—Betamethasone—psoriasis	8.39e-05	0.000553	CcSEcCtD
Deferoxamine—Body temperature increased—Cyclosporine—psoriasis	8.37e-05	0.000551	CcSEcCtD
Deferoxamine—Abdominal pain—Cyclosporine—psoriasis	8.37e-05	0.000551	CcSEcCtD
Deferoxamine—Vomiting—Mycophenolic acid—psoriasis	8.32e-05	0.000548	CcSEcCtD
Deferoxamine—Pain—Prednisolone—psoriasis	8.24e-05	0.000543	CcSEcCtD
Deferoxamine—Urticaria—Mycophenolate mofetil—psoriasis	8.21e-05	0.000541	CcSEcCtD
Deferoxamine—Headache—Mycophenolic acid—psoriasis	8.2e-05	0.00054	CcSEcCtD
Deferoxamine—Abdominal pain—Mycophenolate mofetil—psoriasis	8.17e-05	0.000538	CcSEcCtD
Deferoxamine—Body temperature increased—Mycophenolate mofetil—psoriasis	8.17e-05	0.000538	CcSEcCtD
Deferoxamine—Urinary tract disorder—Methotrexate—psoriasis	8.13e-05	0.000536	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Hydrocortisone—psoriasis	8.13e-05	0.000535	CcSEcCtD
Deferoxamine—Vision blurred—Prednisone—psoriasis	8.09e-05	0.000533	CcSEcCtD
Deferoxamine—Urethral disorder—Methotrexate—psoriasis	8.07e-05	0.000532	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Triamcinolone—psoriasis	8.07e-05	0.000532	CcSEcCtD
Deferoxamine—Pain—Hydrocortisone—psoriasis	8.05e-05	0.00053	CcSEcCtD
Deferoxamine—Anaphylactic shock—Betamethasone—psoriasis	8.04e-05	0.00053	CcSEcCtD
Deferoxamine—Anaphylactic shock—Dexamethasone—psoriasis	8.04e-05	0.00053	CcSEcCtD
Deferoxamine—Oedema—Dexamethasone—psoriasis	8.04e-05	0.00053	CcSEcCtD
Deferoxamine—Oedema—Betamethasone—psoriasis	8.04e-05	0.00053	CcSEcCtD
Deferoxamine—Infection—Dexamethasone—psoriasis	7.99e-05	0.000526	CcSEcCtD
Deferoxamine—Infection—Betamethasone—psoriasis	7.99e-05	0.000526	CcSEcCtD
Deferoxamine—Paraesthesia—Triamcinolone—psoriasis	7.96e-05	0.000524	CcSEcCtD
Deferoxamine—Visual impairment—Methotrexate—psoriasis	7.94e-05	0.000523	CcSEcCtD
Deferoxamine—Shock—Dexamethasone—psoriasis	7.91e-05	0.000521	CcSEcCtD
Deferoxamine—Shock—Betamethasone—psoriasis	7.91e-05	0.000521	CcSEcCtD
Deferoxamine—Dyspnoea—Triamcinolone—psoriasis	7.9e-05	0.00052	CcSEcCtD
Deferoxamine—Nervous system disorder—Dexamethasone—psoriasis	7.89e-05	0.000519	CcSEcCtD
Deferoxamine—Nervous system disorder—Betamethasone—psoriasis	7.89e-05	0.000519	CcSEcCtD
Deferoxamine—Thrombocytopenia—Betamethasone—psoriasis	7.87e-05	0.000519	CcSEcCtD
Deferoxamine—Thrombocytopenia—Dexamethasone—psoriasis	7.87e-05	0.000519	CcSEcCtD
Deferoxamine—Tachycardia—Betamethasone—psoriasis	7.85e-05	0.000517	CcSEcCtD
Deferoxamine—Tachycardia—Dexamethasone—psoriasis	7.85e-05	0.000517	CcSEcCtD
Deferoxamine—Angioedema—Prednisone—psoriasis	7.84e-05	0.000516	CcSEcCtD
Deferoxamine—Hypersensitivity—Cyclosporine—psoriasis	7.8e-05	0.000514	CcSEcCtD
Deferoxamine—Nausea—Mycophenolic acid—psoriasis	7.78e-05	0.000512	CcSEcCtD
Deferoxamine—Eye disorder—Methotrexate—psoriasis	7.7e-05	0.000507	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Hydrocortisone—psoriasis	7.7e-05	0.000507	CcSEcCtD
Deferoxamine—Tinnitus—Methotrexate—psoriasis	7.68e-05	0.000506	CcSEcCtD
Deferoxamine—Urticaria—Prednisolone—psoriasis	7.66e-05	0.000504	CcSEcCtD
Deferoxamine—Hypersensitivity—Mycophenolate mofetil—psoriasis	7.61e-05	0.000501	CcSEcCtD
Deferoxamine—Pain—Triamcinolone—psoriasis	7.58e-05	0.000499	CcSEcCtD
Deferoxamine—Hypotension—Betamethasone—psoriasis	7.51e-05	0.000495	CcSEcCtD
Deferoxamine—Hypotension—Dexamethasone—psoriasis	7.51e-05	0.000495	CcSEcCtD
Deferoxamine—Pruritus—Cyclosporine—psoriasis	7.49e-05	0.000494	CcSEcCtD
Deferoxamine—Urticaria—Hydrocortisone—psoriasis	7.48e-05	0.000493	CcSEcCtD
Deferoxamine—Angiopathy—Methotrexate—psoriasis	7.47e-05	0.000492	CcSEcCtD
Deferoxamine—Immune system disorder—Methotrexate—psoriasis	7.44e-05	0.00049	CcSEcCtD
Deferoxamine—Body temperature increased—Hydrocortisone—psoriasis	7.44e-05	0.00049	CcSEcCtD
Deferoxamine—Abdominal pain—Hydrocortisone—psoriasis	7.44e-05	0.00049	CcSEcCtD
Deferoxamine—Convulsion—Prednisone—psoriasis	7.43e-05	0.00049	CcSEcCtD
Deferoxamine—Mediastinal disorder—Methotrexate—psoriasis	7.42e-05	0.000489	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Dexamethasone—psoriasis	7.33e-05	0.000483	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Betamethasone—psoriasis	7.33e-05	0.000483	CcSEcCtD
Deferoxamine—Pruritus—Mycophenolate mofetil—psoriasis	7.31e-05	0.000481	CcSEcCtD
Deferoxamine—Arthralgia—Prednisone—psoriasis	7.3e-05	0.000481	CcSEcCtD
Deferoxamine—Myalgia—Prednisone—psoriasis	7.3e-05	0.000481	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	7.25e-05	0.000478	CcSEcCtD
Deferoxamine—Diarrhoea—Cyclosporine—psoriasis	7.25e-05	0.000477	CcSEcCtD
Deferoxamine—Paraesthesia—Dexamethasone—psoriasis	7.22e-05	0.000476	CcSEcCtD
Deferoxamine—Paraesthesia—Betamethasone—psoriasis	7.22e-05	0.000476	CcSEcCtD
Deferoxamine—Erythema—Methotrexate—psoriasis	7.17e-05	0.000472	CcSEcCtD
Deferoxamine—Hypersensitivity—Prednisolone—psoriasis	7.1e-05	0.000468	CcSEcCtD
Deferoxamine—Diarrhoea—Mycophenolate mofetil—psoriasis	7.07e-05	0.000466	CcSEcCtD
Deferoxamine—Urticaria—Triamcinolone—psoriasis	7.04e-05	0.000464	CcSEcCtD
Deferoxamine—Body temperature increased—Triamcinolone—psoriasis	7.01e-05	0.000461	CcSEcCtD
Deferoxamine—Dizziness—Cyclosporine—psoriasis	7e-05	0.000461	CcSEcCtD
Deferoxamine—Anaphylactic shock—Prednisone—psoriasis	7e-05	0.000461	CcSEcCtD
Deferoxamine—Oedema—Prednisone—psoriasis	7e-05	0.000461	CcSEcCtD
Deferoxamine—Infection—Prednisone—psoriasis	6.96e-05	0.000458	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Dexamethasone—psoriasis	6.94e-05	0.000457	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Betamethasone—psoriasis	6.94e-05	0.000457	CcSEcCtD
Deferoxamine—Hypersensitivity—Hydrocortisone—psoriasis	6.93e-05	0.000457	CcSEcCtD
Deferoxamine—Shock—Prednisone—psoriasis	6.89e-05	0.000454	CcSEcCtD
Deferoxamine—Pain—Betamethasone—psoriasis	6.88e-05	0.000453	CcSEcCtD
Deferoxamine—Pain—Dexamethasone—psoriasis	6.88e-05	0.000453	CcSEcCtD
Deferoxamine—Nervous system disorder—Prednisone—psoriasis	6.87e-05	0.000452	CcSEcCtD
Deferoxamine—Tachycardia—Prednisone—psoriasis	6.83e-05	0.00045	CcSEcCtD
Deferoxamine—Dizziness—Mycophenolate mofetil—psoriasis	6.83e-05	0.00045	CcSEcCtD
Deferoxamine—Skin disorder—Prednisone—psoriasis	6.8e-05	0.000448	CcSEcCtD
Deferoxamine—Vision blurred—Methotrexate—psoriasis	6.76e-05	0.000445	CcSEcCtD
Deferoxamine—Vomiting—Cyclosporine—psoriasis	6.73e-05	0.000444	CcSEcCtD
Deferoxamine—Pruritus—Hydrocortisone—psoriasis	6.66e-05	0.000439	CcSEcCtD
Deferoxamine—Headache—Cyclosporine—psoriasis	6.63e-05	0.000437	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Betamethasone—psoriasis	6.58e-05	0.000433	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Dexamethasone—psoriasis	6.58e-05	0.000433	CcSEcCtD
Deferoxamine—Vomiting—Mycophenolate mofetil—psoriasis	6.57e-05	0.000433	CcSEcCtD
Deferoxamine—Hypersensitivity—Triamcinolone—psoriasis	6.53e-05	0.00043	CcSEcCtD
Deferoxamine—Headache—Mycophenolate mofetil—psoriasis	6.47e-05	0.000426	CcSEcCtD
Deferoxamine—Diarrhoea—Hydrocortisone—psoriasis	6.44e-05	0.000424	CcSEcCtD
Deferoxamine—Leukopenia—Methotrexate—psoriasis	6.42e-05	0.000423	CcSEcCtD
Deferoxamine—Urticaria—Dexamethasone—psoriasis	6.39e-05	0.000421	CcSEcCtD
Deferoxamine—Urticaria—Betamethasone—psoriasis	6.39e-05	0.000421	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Prednisone—psoriasis	6.38e-05	0.00042	CcSEcCtD
Deferoxamine—Dizziness—Prednisolone—psoriasis	6.37e-05	0.00042	CcSEcCtD
Deferoxamine—Body temperature increased—Dexamethasone—psoriasis	6.36e-05	0.000419	CcSEcCtD
Deferoxamine—Body temperature increased—Betamethasone—psoriasis	6.36e-05	0.000419	CcSEcCtD
Deferoxamine—Abdominal pain—Dexamethasone—psoriasis	6.36e-05	0.000419	CcSEcCtD
Deferoxamine—Abdominal pain—Betamethasone—psoriasis	6.36e-05	0.000419	CcSEcCtD
Deferoxamine—Nausea—Cyclosporine—psoriasis	6.29e-05	0.000414	CcSEcCtD
Deferoxamine—Paraesthesia—Prednisone—psoriasis	6.29e-05	0.000414	CcSEcCtD
Deferoxamine—Pruritus—Triamcinolone—psoriasis	6.27e-05	0.000413	CcSEcCtD
Deferoxamine—Dizziness—Hydrocortisone—psoriasis	6.22e-05	0.00041	CcSEcCtD
Deferoxamine—Convulsion—Methotrexate—psoriasis	6.21e-05	0.000409	CcSEcCtD
Deferoxamine—Nausea—Mycophenolate mofetil—psoriasis	6.14e-05	0.000404	CcSEcCtD
Deferoxamine—Arthralgia—Methotrexate—psoriasis	6.1e-05	0.000402	CcSEcCtD
Deferoxamine—Myalgia—Methotrexate—psoriasis	6.1e-05	0.000402	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	6.06e-05	0.000399	CcSEcCtD
Deferoxamine—Headache—Prednisolone—psoriasis	6.04e-05	0.000398	CcSEcCtD
Deferoxamine—Vomiting—Hydrocortisone—psoriasis	5.98e-05	0.000394	CcSEcCtD
Deferoxamine—Headache—Hydrocortisone—psoriasis	5.9e-05	0.000388	CcSEcCtD
Deferoxamine—Dizziness—Triamcinolone—psoriasis	5.86e-05	0.000386	CcSEcCtD
Deferoxamine—Anaphylactic shock—Methotrexate—psoriasis	5.85e-05	0.000386	CcSEcCtD
Deferoxamine—Infection—Methotrexate—psoriasis	5.81e-05	0.000383	CcSEcCtD
Deferoxamine—Nervous system disorder—Methotrexate—psoriasis	5.74e-05	0.000378	CcSEcCtD
Deferoxamine—Thrombocytopenia—Methotrexate—psoriasis	5.73e-05	0.000377	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Prednisone—psoriasis	5.73e-05	0.000377	CcSEcCtD
Deferoxamine—Nausea—Prednisolone—psoriasis	5.72e-05	0.000377	CcSEcCtD
Deferoxamine—Pruritus—Dexamethasone—psoriasis	5.69e-05	0.000375	CcSEcCtD
Deferoxamine—Pruritus—Betamethasone—psoriasis	5.69e-05	0.000375	CcSEcCtD
Deferoxamine—Skin disorder—Methotrexate—psoriasis	5.68e-05	0.000374	CcSEcCtD
Deferoxamine—Vomiting—Triamcinolone—psoriasis	5.63e-05	0.000371	CcSEcCtD
Deferoxamine—Nausea—Hydrocortisone—psoriasis	5.59e-05	0.000368	CcSEcCtD
Deferoxamine—Urticaria—Prednisone—psoriasis	5.56e-05	0.000366	CcSEcCtD
Deferoxamine—Headache—Triamcinolone—psoriasis	5.55e-05	0.000366	CcSEcCtD
Deferoxamine—Abdominal pain—Prednisone—psoriasis	5.54e-05	0.000365	CcSEcCtD
Deferoxamine—Body temperature increased—Prednisone—psoriasis	5.54e-05	0.000365	CcSEcCtD
Deferoxamine—Diarrhoea—Dexamethasone—psoriasis	5.5e-05	0.000362	CcSEcCtD
Deferoxamine—Diarrhoea—Betamethasone—psoriasis	5.5e-05	0.000362	CcSEcCtD
Deferoxamine—Hypotension—Methotrexate—psoriasis	5.47e-05	0.00036	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Methotrexate—psoriasis	5.33e-05	0.000351	CcSEcCtD
Deferoxamine—Dizziness—Dexamethasone—psoriasis	5.32e-05	0.00035	CcSEcCtD
Deferoxamine—Dizziness—Betamethasone—psoriasis	5.32e-05	0.00035	CcSEcCtD
Deferoxamine—Nausea—Triamcinolone—psoriasis	5.26e-05	0.000347	CcSEcCtD
Deferoxamine—Paraesthesia—Methotrexate—psoriasis	5.25e-05	0.000346	CcSEcCtD
Deferoxamine—Dyspnoea—Methotrexate—psoriasis	5.22e-05	0.000344	CcSEcCtD
Deferoxamine—Hypersensitivity—Prednisone—psoriasis	5.16e-05	0.00034	CcSEcCtD
Deferoxamine—Vomiting—Betamethasone—psoriasis	5.11e-05	0.000337	CcSEcCtD
Deferoxamine—Vomiting—Dexamethasone—psoriasis	5.11e-05	0.000337	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Methotrexate—psoriasis	5.05e-05	0.000333	CcSEcCtD
Deferoxamine—Headache—Dexamethasone—psoriasis	5.04e-05	0.000332	CcSEcCtD
Deferoxamine—Headache—Betamethasone—psoriasis	5.04e-05	0.000332	CcSEcCtD
Deferoxamine—Pain—Methotrexate—psoriasis	5e-05	0.00033	CcSEcCtD
Deferoxamine—Pruritus—Prednisone—psoriasis	4.95e-05	0.000326	CcSEcCtD
Deferoxamine—Diarrhoea—Prednisone—psoriasis	4.79e-05	0.000316	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Methotrexate—psoriasis	4.79e-05	0.000315	CcSEcCtD
Deferoxamine—Nausea—Dexamethasone—psoriasis	4.78e-05	0.000315	CcSEcCtD
Deferoxamine—Nausea—Betamethasone—psoriasis	4.78e-05	0.000315	CcSEcCtD
Deferoxamine—Urticaria—Methotrexate—psoriasis	4.65e-05	0.000306	CcSEcCtD
Deferoxamine—Dizziness—Prednisone—psoriasis	4.63e-05	0.000305	CcSEcCtD
Deferoxamine—Abdominal pain—Methotrexate—psoriasis	4.63e-05	0.000305	CcSEcCtD
Deferoxamine—Body temperature increased—Methotrexate—psoriasis	4.63e-05	0.000305	CcSEcCtD
Deferoxamine—Vomiting—Prednisone—psoriasis	4.45e-05	0.000293	CcSEcCtD
Deferoxamine—Headache—Prednisone—psoriasis	4.39e-05	0.000289	CcSEcCtD
Deferoxamine—Hypersensitivity—Methotrexate—psoriasis	4.31e-05	0.000284	CcSEcCtD
Deferoxamine—Nausea—Prednisone—psoriasis	4.16e-05	0.000274	CcSEcCtD
Deferoxamine—Pruritus—Methotrexate—psoriasis	4.14e-05	0.000273	CcSEcCtD
Deferoxamine—Diarrhoea—Methotrexate—psoriasis	4e-05	0.000264	CcSEcCtD
Deferoxamine—Dizziness—Methotrexate—psoriasis	3.87e-05	0.000255	CcSEcCtD
Deferoxamine—Vomiting—Methotrexate—psoriasis	3.72e-05	0.000245	CcSEcCtD
Deferoxamine—Headache—Methotrexate—psoriasis	3.67e-05	0.000242	CcSEcCtD
Deferoxamine—Nausea—Methotrexate—psoriasis	3.48e-05	0.000229	CcSEcCtD
